MIRA PHARMACEUTICALS, INC. (MIRA): Nasdaq/NYSE listing notice — MIRA receives Nasdaq minimum equity deficiency notice; equity $2.2M vs $2.5M

MIRA PHARMACEUTICALS, INC.

Stockholders' equity $2,199,750 as of Dec 31, 2024, below Nasdaq's $2.5M minimum requirement under Rule 5550(b)(1).
Company has 45 days to submit a compliance plan by May 23, 2025; Nasdaq may grant up to 180-day extension.
Plans to complete SKNY Pharmaceuticals acquisition with $5M capital infusion to boost equity.
Also in discussions with strategic investors to strengthen capital position; trading continues uninterrupted.
Phase 1 trial of Ketamir-2 for neuropathic pain ongoing; first subject dosed.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

MIRA PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 8, 2025, MIRA Pharmaceuticals, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Staff indicating that, based on the Company’s stockholders’ equity of $2,199,750 as of December 31, 2024, the Company does not currently meet the minimum stockholders’ equity requirement of $2.5 million as set forth under Nasdaq Listing Rule 5550(b)(1). Importantly, this notice does not affect the Company’s listing status or the trading of its common stock, which will continue uninterrupted on the Nasdaq Capital Market under the ticker symbol “MIRA.” In accordance with Nasdaq proc

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

MIRA PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001641172-25-003889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.